AU2004276341B2 - Pyrazolopyrrole derivatives as protein kinase inhibitors - Google Patents

Pyrazolopyrrole derivatives as protein kinase inhibitors Download PDF

Info

Publication number
AU2004276341B2
AU2004276341B2 AU2004276341A AU2004276341A AU2004276341B2 AU 2004276341 B2 AU2004276341 B2 AU 2004276341B2 AU 2004276341 A AU2004276341 A AU 2004276341A AU 2004276341 A AU2004276341 A AU 2004276341A AU 2004276341 B2 AU2004276341 B2 AU 2004276341B2
Authority
AU
Australia
Prior art keywords
independently selected
aliphatic
compound
nitrogen
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004276341A
Other languages
English (en)
Other versions
AU2004276341A1 (en
Inventor
Hayley Binch
Simon Everitt
Francesca Mazzei
Daniel Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2004276341A1 publication Critical patent/AU2004276341A1/en
Application granted granted Critical
Publication of AU2004276341B2 publication Critical patent/AU2004276341B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004276341A 2003-09-23 2004-09-23 Pyrazolopyrrole derivatives as protein kinase inhibitors Ceased AU2004276341B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50523603P 2003-09-23 2003-09-23
US60/505,236 2003-09-23
PCT/US2004/031610 WO2005030776A1 (en) 2003-09-23 2004-09-23 Pyrazolopyrrole derivatives as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2004276341A1 AU2004276341A1 (en) 2005-04-07
AU2004276341B2 true AU2004276341B2 (en) 2011-04-14

Family

ID=34392996

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004276341A Ceased AU2004276341B2 (en) 2003-09-23 2004-09-23 Pyrazolopyrrole derivatives as protein kinase inhibitors

Country Status (7)

Country Link
US (2) US7652135B2 (enExample)
EP (1) EP1668013B1 (enExample)
JP (1) JP2007506787A (enExample)
AT (1) ATE546452T1 (enExample)
AU (1) AU2004276341B2 (enExample)
CA (1) CA2539549A1 (enExample)
WO (1) WO2005030776A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG146683A1 (en) * 2003-09-17 2008-10-30 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
MY151455A (en) * 2005-12-21 2014-05-30 Pfizer Prod Inc Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
EP1999131B1 (en) 2006-03-03 2013-10-23 Nerviano Medical Sciences S.r.l. Bicyclo-pyrazoles active as kinase inhibitors
CA2646316C (en) * 2006-03-15 2016-05-24 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
WO2008070823A2 (en) 2006-12-07 2008-06-12 University Of South Florida Substrate-mimetic akt inhibitor
CN101675052A (zh) 2007-04-12 2010-03-17 辉瑞大药厂 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
MX2009012525A (es) * 2007-05-25 2009-12-09 Elan Pharm Inc Pirazol-pirrolidinas como inhibidores de gamma secretasa.
MX2012002385A (es) * 2009-09-21 2012-04-02 Hoffmann La Roche Inhibidores macrociclicos de cinasa janus.
KR102020485B1 (ko) 2013-01-11 2019-09-11 삼성디스플레이 주식회사 블록 공중합체, 그 형성 방법 및 패턴 형성 방법
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2016109689A2 (en) * 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
CA3005723A1 (en) * 2015-11-20 2017-05-26 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
US20190290656A1 (en) 2015-12-30 2019-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pt(iv) prodrugs
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
WO2021020363A1 (ja) * 2019-07-29 2021-02-04 武田薬品工業株式会社 複素環化合物
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
CN115073471B (zh) * 2021-03-11 2023-03-21 沈阳药科大学 吡唑并四氢吡咯类衍生物、其制备方法和在医药上的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171357A1 (en) * 2000-08-10 2003-09-11 Deniele Fancelli Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003244649A1 (en) * 2002-07-25 2004-02-23 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27383A (da) 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
US6677310B1 (en) 1999-04-21 2004-01-13 Nabi Ring-expanded nucleosides and nucleotides
US5843912A (en) 1994-07-06 1998-12-01 Universy Of Maryland Ring-expanded nucleosides and nucleotides
DE4337611A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4337609A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
US6187774B1 (en) * 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
NZ511674A (en) 1998-12-23 2003-11-28 Du Pont Pharm Co Nitrogen containing heterobicycles as factor Xa inhibitors
WO2000071511A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AU2001290912A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002083648A1 (fr) 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
US20060100233A1 (en) 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
BRPI0408486A (pt) * 2003-03-11 2006-04-04 Pharmacia Italia Spa derivados de biciclopirazol ativos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas compreendendo-os
US7141568B2 (en) * 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171357A1 (en) * 2000-08-10 2003-09-11 Deniele Fancelli Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003244649A1 (en) * 2002-07-25 2004-02-23 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
WO2005030776A1 (en) 2005-04-07
US20050101594A1 (en) 2005-05-12
US20100087467A1 (en) 2010-04-08
CA2539549A1 (en) 2005-04-07
US7652135B2 (en) 2010-01-26
JP2007506787A (ja) 2007-03-22
EP1668013A1 (en) 2006-06-14
US8642779B2 (en) 2014-02-04
AU2004276341A1 (en) 2005-04-07
EP1668013B1 (en) 2012-02-22
ATE546452T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
US8642779B2 (en) Compositions useful as inhibitors of protein kinases
EP1417205B1 (en) Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
JP4541695B2 (ja) プロテインキナーゼインヒビターとしての５−（２−アミノピリミジン−４−イル）ベンズイソキサゾール
JP4316893B2 (ja) Ｓｒｃおよび他のプロテインキナーゼのインヒビター
US7179826B2 (en) Compositions useful as inhibitors of protein kinases
DE60214701T2 (de) Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
US7091343B2 (en) Compositions useful as inhibitors of protein kinases
AU2003212833C1 (en) Indazole compounds useful as protein kinase inhibitors
WO2005039564A1 (en) Phthalimide compounds useful as protein kinase inhibitors
AU2003212833A1 (en) Indazole compounds useful as protein kinase inhibitors
US20090012091A1 (en) Oximide derivatives and their therapeutical application
US20040009981A1 (en) Compositions useful as inhibitors of protein kinases
EP1575959A2 (en) Compositions useful as inhibitors of protein kinases
JP2004532234A (ja) トリアゾール由来キナーゼインヒビターおよびその使用
JP2004538266A (ja) ピラゾール由来のキナーゼインヒビター
US20060142572A1 (en) Inhibitors of ERK protein kinase and uses thereof
WO2004041789A1 (en) Compositions useful as inhibitors of jak and other protein kinases
JP2007506787A5 (enExample)
US7501415B2 (en) Selective inhibitors of ERK protein kinase and uses thereof
HK1065540B (en) Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired